Dr. Pooja A Chawla is working as a Professor, at the University Institute of Pharmaceutical Sciences, Baba Farid University of Health Sciences, Faridkot, Punjab, India. She has 22 years of experience in the research, discovery, and development of biologically active pharmaceuticals. Dr. Chawla holds a PhD degree in Pharmaceutical Sciences with a specialization in Pharmaceutical Chemistry and has published 6 books, 25 book chapters, and more than 150 papers in national/international journals and is serving as a reviewer for international journals of repute. Dr. Pooja is also privileged to serve as guest editor of two reputed journals CNS & Neurological Disorders - Drug Targets IF 2.8 and Current Organic Chemistry IF 2.5) of Bentham Sciences. She has been appointed as Academic editor of PLOS ONE journal IF 3.2 and recently she has been appointed as Assistant editor for Health Sciences Review Journal by Elsevier publishers. She has guided more than 60 postgraduate projects and her research team consists of 6 Masters and 4 Doctoral research scholars. Her area of research interest focuses on the design and synthesis of various heterocyclic moieties including 4-Thiazolidinones, 2,4-Thiazolidiedione, Coumarin, Pyrazolines, Schiff’s base derivatives to name a few for the discovery of medicinally important agents as anticonvulsants, antidepressants, anticancer, anti Alzheimer’s agents. She is well-versed with method development and validation and guiding research scholars in this field. Dr. Raimar Löbenberg holds a BSc in pharmacy from the Johannes Gutenberg-University in Mainz, Germany and PhD in pharmaceutics from the Johann Wolfgang Goethe-University in Frankfurt. He joined the University of Alberta in 2000. His research interests are in Biopharmaceutics to predict the oral performance of drugs and botanicals and inhalable nanoparticles to treat lung diseases like cancer or tuberculosis. He is founder and director of the Drug Development and Innovation Centre at the University of Alberta. He was president of the Canadian Society for Pharmaceutical Sciences 2014 & 2015. He is member of the United States Pharmacopeia Dietary Supplement Expert Committee. He is Vice Chair of the Specialty Committee of Traditional Chinese Medicine in Pharmaceutics of the World Foundation of Chinese Medicine Science. He is member of the Health Canada Scientific Advisory Committee on Pharmaceutical Sciences and Clinical Pharmacology.Dr. Kamal Dua is an Associate Professor in the Discipline of Pharmacy at the Graduate School of Health, University of Technology Sydney (UTS), Australia. He has research experience of over 13 years in the field of drug delivery systems targeting inflammatory diseases. Dr. Dua is also a Node Leader of Drug Delivery Research in the Centre for Inflammation at Centenary Institute/UTS, where the targets identified from the research projects are pursued to develop novel formulations as the first step towards translation into clinics. Dr. Dua research in two complementary areas; drug delivery and immunology, specifically addressing how these disciplines can advance one another, helping the community to live longer and healthier. This is evidenced by his extensive publication record in reputed journals. Dr. Dua’s research interests focus on harnessing the pharmaceutical potential of modulating critical regulators such as Interleukins and microRNAs and developing new and effective drug delivery formulations for the management of chronic airway diseases. He has published more than 100 research articles in peer-reviewed international journals and authored or co-authored four books. He is an active member of many national and international professional societies.Vinay Parikh is an Associate Professor in the Department of Psychology at Temple University (Philadelphia). He also serves as the Director of Neuroscience Program in Temple’s College of Liberal Arts and provides strategic leadership, direction, and guidance for all educational and professional activities in the program. Dr. Parikh has successfully directed multiple research projects, resulting in notable contributions to the understanding of neural mechanisms underlying cognitive decline in age-related neurodegenerative and psychiatric disorders. His research has also opened new avenues to develop cognition therapies. Dr. Parikh has published more than 90 scientific articles and book chapters in areas of systems and behavioral neuroscience, biological psychiatry, and pharmacology, and serves on several editorial boards of journals. He also regularly serves on scientific advisory and review committees of numerous biomedical research agencies including the National Institute of Health, Alzheimer’s Association, and Michael J Fox Foundation.Dr. Viney Chawla is working as Professor and Principal at University Institute of Pharmaceutical Sciences and Research, Baba Farid University of Health Sciences, Punjab, India, He has 25 Years of experience in the research, formulation and development of solid lipid nanoparticles, microspheres, nanostructured lipid carriers. Dr. Chawla holds a Ph D Degree in Pharmaceutics and has Published 3 Books, 30 Book Chapters and more than 100 Papers in National/International Journals and is serving as a Reviewer for International Journals of repute. He has guided 40 Post Graduate Projects and his research team consists of 9 Masters and 4 Doctoral Research Scholars.

Select Guide Rating

• Part I – Introduction to Drug delivery to the CNS1. General physiology and function of brainAnoop Kumar I2. Drug Delivery to Brain: Formulation Challenges and Potential ApproachesAshish Baldi, Manisha Kumari and Akshay Kumar3. Possible targets in the management of various CNS disordersViney Chawla, Pooja A. Chawla, Ankur Kumar and Bhupender Nehra4. Antioxidants and their possible benefits in neurodegenerationPooja A. Chawla, Viney Chawla, Keshav Taruneshwar Jha and Gouranga Sundar Roy5. Prodrug approaches for delivering CNS active agentsPooja A. Chawla, Viney Chawla, Nikita Sharma and Debashree Debashish Das6. Traditional practices in CNS drug deliveryR K Narang and Pooja A. Chawla7. Emerging need of Novel Drug Delivery Systems in management of CNS disordersViney Chawla, Pooja A. Chawla, Neha Jain, Manisha Pandey, Ms Triveni and Aditi Sinha8. Nose to brain drug delivery through advanced Drug Delivery SystemsMonica Gulati9. PBPK modeling for CNS DeliveryNAGENDRA SINGH CHAUHANPart II – Novel Drug Delivery Systems to specific CNS Disorders10. Superparamagnetic Iron Oxide Nanoparticles and their Potential Role in the Diagnosis and Therapeutics of Various Neurological DisordersBhupinder Singh Bhoop, Anjali Pant, Gurpal Singh, Ravi Pratap Barnwal, Sumant Saini and Atul Jain11. Novel Drug Delivery Systems in treating epilepsyREYAZ HASSAN, Jasreen Uppal and Apporva Chawla12. Novel Drug Delivery Systems in the management of Parkinson’s DiseaseVimal Arora13. Role of Novel Drug Delivery Systems in managing Alzheimer’s DiseaseViney Chawla, Pooja A. Chawla, Ankur Kumar, Bhupender Nehra, Ms Chahat and Abhimannu Shome14. Novel Drug Delivery Systems in the management of Huntington’s DiseaseMonica Gulati15. Novel Drug Delivery Systems in the management of multiple sclerosisDileep Kumar and Gadde Shareena16. Role of Novel Drug Delivery Systems in delivering antidepressant drugs to the brainPooja A. Chawla, Dilpreet Singh, Viney Chawla, Kamal Dua, Amrinder Singh, Ms Amisha and Namandeep Raj17. Delivering cancer chemotherapeutics to the brain through Novel Drug Delivery SystemsPooja A. Chawla18. Novel Drug Delivery Systems in the management of SchizophreniaDileep Kumar and Gadde Shareena19. Prospects of Novel Drug Delivery Systems in treating cerebral palsyMolakpogu Ravindra Babu, Sukriti Vishwas, Monica Gulati, Kamal Dua, Sachin Kumar Singh, Prathap Madeswara Gupta and Palakurthi Yanadaiah20. Novel Treatment in Managing AutismYadu Nandan Dey, Dharmendra Kumar, Manju Singh and Deependra Singh21. Novel Drug Delivery Systems in amyotrophic lateral sclerosisDevidas S. Bhagat, Pooja A. Chawla, Gurvinder S. Bumbrah, Dattatraya Pansare, Bapu R Thorat and Digambar D Gaikwad22. Novel Drug Delivery Systems in cerebral vascular disorders, transient ischaemic attack and stroke interventionsDharmendra Kumar, Deependra Singh and Manju Singh23. Treating meningitis through Novel Drug Delivery SystemsNAGENDRA SINGH CHAUHAN24. Treatment of CNS infections in AIDS positive patients through Novel Drug Delivery SystemsSS Pancholi, Alok Shiomurti Tripathi and Partha Saha25. Novel Drug Delivery Systems in the management of myasthenia gravisDharmendra Kumar26. Etiology and Treatment Challenges for Neurotraumatic and Psychiatric DisordersMohd. Farooq Shaikh and Alina Arulsamy27. Trends in delivery of drugs to brain for treatment of neuropathySukhbir Singh, Neelam Sharma, Ishrat Zahoor and Sandeep Arora28. Delivery of antimigraine drugs to brain through Novel Drug Delivery SystemsManisha Pandey29. Treatment of heavy metal induced neurotoxicity via advanced drug delivery systemsArun Kumar, Mr Abhinav, Mahesh Rachamalla, Mohammad Ali, Sneha Navin, DHRUV KUMAR and Ashok Kumar GhoshPart III – Clinical Trials and Future Prospects30. Exploring the potential of artificial intelligence in drug delivery to brainVimal Arora31. Advanced Drug Delivery Systems in the Management of CNS DisordersShamsher Singh, Pooja A. Chawla, Md Reyaz Alam and Anjalee Bhratee32. Future prospects and Challenges to CNS drug deliverySushama Talegaonkar Sr. and Monalisa Mishra

Dr. Pooja A Chawla is working as a Professor, at the University Institute of Pharmaceutical Sciences, Baba Farid University of Health Sciences, Faridkot, Punjab, India. She has 22 years of experience in the research, discovery, and development of biologically active pharmaceuticals. Dr. Chawla holds a PhD degree in Pharmaceutical Sciences with a specialization in Pharmaceutical Chemistry and has published 6 books, 25 book chapters, and more than 150 papers in national/international journals and is serving as a reviewer for international journals of repute. Dr. Pooja is also privileged to serve as guest editor of two reputed journals CNS & Neurological Disorders - Drug Targets IF 2.8 and Current Organic Chemistry IF 2.5) of Bentham Sciences. She has been appointed as Academic editor of PLOS ONE journal IF 3.2 and recently she has been appointed as Assistant editor for Health Sciences Review Journal by Elsevier publishers. She has guided more than 60 postgraduate projects and her research team consists of 6 Masters and 4 Doctoral research scholars. Her area of research interest focuses on the design and synthesis of various heterocyclic moieties including 4-Thiazolidinones, 2,4-Thiazolidiedione, Coumarin, Pyrazolines, Schiff’s base derivatives to name a few for the discovery of medicinally important agents as anticonvulsants, antidepressants, anticancer, anti Alzheimer’s agents. She is well-versed with method development and validation and guiding research scholars in this field. Dr. Raimar Löbenberg holds a BSc in pharmacy from the Johannes Gutenberg-University in Mainz, Germany and PhD in pharmaceutics from the Johann Wolfgang Goethe-University in Frankfurt. He joined the University of Alberta in 2000. His research interests are in Biopharmaceutics to predict the oral performance of drugs and botanicals and inhalable nanoparticles to treat lung diseases like cancer or tuberculosis. He is founder and director of the Drug Development and Innovation Centre at the University of Alberta. He was president of the Canadian Society for Pharmaceutical Sciences 2014 & 2015. He is member of the United States Pharmacopeia Dietary Supplement Expert Committee. He is Vice Chair of the Specialty Committee of Traditional Chinese Medicine in Pharmaceutics of the World Foundation of Chinese Medicine Science. He is member of the Health Canada Scientific Advisory Committee on Pharmaceutical Sciences and Clinical Pharmacology.Dr. Kamal Dua is an Associate Professor in the Discipline of Pharmacy at the Graduate School of Health, University of Technology Sydney (UTS), Australia. He has research experience of over 13 years in the field of drug delivery systems targeting inflammatory diseases. Dr. Dua is also a Node Leader of Drug Delivery Research in the Centre for Inflammation at Centenary Institute/UTS, where the targets identified from the research projects are pursued to develop novel formulations as the first step towards translation into clinics. Dr. Dua research in two complementary areas; drug delivery and immunology, specifically addressing how these disciplines can advance one another, helping the community to live longer and healthier. This is evidenced by his extensive publication record in reputed journals. Dr. Dua’s research interests focus on harnessing the pharmaceutical potential of modulating critical regulators such as Interleukins and microRNAs and developing new and effective drug delivery formulations for the management of chronic airway diseases. He has published more than 100 research articles in peer-reviewed international journals and authored or co-authored four books. He is an active member of many national and international professional societies.Vinay Parikh is an Associate Professor in the Department of Psychology at Temple University (Philadelphia). He also serves as the Director of Neuroscience Program in Temple’s College of Liberal Arts and provides strategic leadership, direction, and guidance for all educational and professional activities in the program. Dr. Parikh has successfully directed multiple research projects, resulting in notable contributions to the understanding of neural mechanisms underlying cognitive decline in age-related neurodegenerative and psychiatric disorders. His research has also opened new avenues to develop cognition therapies. Dr. Parikh has published more than 90 scientific articles and book chapters in areas of systems and behavioral neuroscience, biological psychiatry, and pharmacology, and serves on several editorial boards of journals. He also regularly serves on scientific advisory and review committees of numerous biomedical research agencies including the National Institute of Health, Alzheimer’s Association, and Michael J Fox Foundation.Dr. Viney Chawla is working as Professor and Principal at University Institute of Pharmaceutical Sciences and Research, Baba Farid University of Health Sciences, Punjab, India, He has 25 Years of experience in the research, formulation and development of solid lipid nanoparticles, microspheres, nanostructured lipid carriers. Dr. Chawla holds a Ph D Degree in Pharmaceutics and has Published 3 Books, 30 Book Chapters and more than 100 Papers in National/International Journals and is serving as a Reviewer for International Journals of repute. He has guided 40 Post Graduate Projects and his research team consists of 9 Masters and 4 Doctoral Research Scholars.

Select Guide Rating

• Part I – Introduction to Drug delivery to the CNS1. General physiology and function of brainAnoop Kumar I2. Drug Delivery to Brain: Formulation Challenges and Potential ApproachesAshish Baldi, Manisha Kumari and Akshay Kumar3. Possible targets in the management of various CNS disordersViney Chawla, Pooja A. Chawla, Ankur Kumar and Bhupender Nehra4. Antioxidants and their possible benefits in neurodegenerationPooja A. Chawla, Viney Chawla, Keshav Taruneshwar Jha and Gouranga Sundar Roy5. Prodrug approaches for delivering CNS active agentsPooja A. Chawla, Viney Chawla, Nikita Sharma and Debashree Debashish Das6. Traditional practices in CNS drug deliveryR K Narang and Pooja A. Chawla7. Emerging need of Novel Drug Delivery Systems in management of CNS disordersViney Chawla, Pooja A. Chawla, Neha Jain, Manisha Pandey, Ms Triveni and Aditi Sinha8. Nose to brain drug delivery through advanced Drug Delivery SystemsMonica Gulati9. PBPK modeling for CNS DeliveryNAGENDRA SINGH CHAUHANPart II – Novel Drug Delivery Systems to specific CNS Disorders10. Superparamagnetic Iron Oxide Nanoparticles and their Potential Role in the Diagnosis and Therapeutics of Various Neurological DisordersBhupinder Singh Bhoop, Anjali Pant, Gurpal Singh, Ravi Pratap Barnwal, Sumant Saini and Atul Jain11. Novel Drug Delivery Systems in treating epilepsyREYAZ HASSAN, Jasreen Uppal and Apporva Chawla12. Novel Drug Delivery Systems in the management of Parkinson’s DiseaseVimal Arora13. Role of Novel Drug Delivery Systems in managing Alzheimer’s DiseaseViney Chawla, Pooja A. Chawla, Ankur Kumar, Bhupender Nehra, Ms Chahat and Abhimannu Shome14. Novel Drug Delivery Systems in the management of Huntington’s DiseaseMonica Gulati15. Novel Drug Delivery Systems in the management of multiple sclerosisDileep Kumar and Gadde Shareena16. Role of Novel Drug Delivery Systems in delivering antidepressant drugs to the brainPooja A. Chawla, Dilpreet Singh, Viney Chawla, Kamal Dua, Amrinder Singh, Ms Amisha and Namandeep Raj17. Delivering cancer chemotherapeutics to the brain through Novel Drug Delivery SystemsPooja A. Chawla18. Novel Drug Delivery Systems in the management of SchizophreniaDileep Kumar and Gadde Shareena19. Prospects of Novel Drug Delivery Systems in treating cerebral palsyMolakpogu Ravindra Babu, Sukriti Vishwas, Monica Gulati, Kamal Dua, Sachin Kumar Singh, Prathap Madeswara Gupta and Palakurthi Yanadaiah20. Novel Treatment in Managing AutismYadu Nandan Dey, Dharmendra Kumar, Manju Singh and Deependra Singh21. Novel Drug Delivery Systems in amyotrophic lateral sclerosisDevidas S. Bhagat, Pooja A. Chawla, Gurvinder S. Bumbrah, Dattatraya Pansare, Bapu R Thorat and Digambar D Gaikwad22. Novel Drug Delivery Systems in cerebral vascular disorders, transient ischaemic attack and stroke interventionsDharmendra Kumar, Deependra Singh and Manju Singh23. Treating meningitis through Novel Drug Delivery SystemsNAGENDRA SINGH CHAUHAN24. Treatment of CNS infections in AIDS positive patients through Novel Drug Delivery SystemsSS Pancholi, Alok Shiomurti Tripathi and Partha Saha25. Novel Drug Delivery Systems in the management of myasthenia gravisDharmendra Kumar26. Etiology and Treatment Challenges for Neurotraumatic and Psychiatric DisordersMohd. Farooq Shaikh and Alina Arulsamy27. Trends in delivery of drugs to brain for treatment of neuropathySukhbir Singh, Neelam Sharma, Ishrat Zahoor and Sandeep Arora28. Delivery of antimigraine drugs to brain through Novel Drug Delivery SystemsManisha Pandey29. Treatment of heavy metal induced neurotoxicity via advanced drug delivery systemsArun Kumar, Mr Abhinav, Mahesh Rachamalla, Mohammad Ali, Sneha Navin, DHRUV KUMAR and Ashok Kumar GhoshPart III – Clinical Trials and Future Prospects30. Exploring the potential of artificial intelligence in drug delivery to brainVimal Arora31. Advanced Drug Delivery Systems in the Management of CNS DisordersShamsher Singh, Pooja A. Chawla, Md Reyaz Alam and Anjalee Bhratee32. Future prospects and Challenges to CNS drug deliverySushama Talegaonkar Sr. and Monalisa Mishra

Dr. Pooja A Chawla is working as a Professor, at the University Institute of Pharmaceutical Sciences, Baba Farid University of Health Sciences, Faridkot, Punjab, India. She has 22 years of experience in the research, discovery, and development of biologically active pharmaceuticals. Dr. Chawla holds a PhD degree in Pharmaceutical Sciences with a specialization in Pharmaceutical Chemistry and has published 6 books, 25 book chapters, and more than 150 papers in national/international journals and is serving as a reviewer for international journals of repute. Dr. Pooja is also privileged to serve as guest editor of two reputed journals CNS & Neurological Disorders - Drug Targets IF 2.8 and Current Organic Chemistry IF 2.5) of Bentham Sciences. She has been appointed as Academic editor of PLOS ONE journal IF 3.2 and recently she has been appointed as Assistant editor for Health Sciences Review Journal by Elsevier publishers. She has guided more than 60 postgraduate projects and her research team consists of 6 Masters and 4 Doctoral research scholars. Her area of research interest focuses on the design and synthesis of various heterocyclic moieties including 4-Thiazolidinones, 2,4-Thiazolidiedione, Coumarin, Pyrazolines, Schiff’s base derivatives to name a few for the discovery of medicinally important agents as anticonvulsants, antidepressants, anticancer, anti Alzheimer’s agents. She is well-versed with method development and validation and guiding research scholars in this field. Dr. Raimar Löbenberg holds a BSc in pharmacy from the Johannes Gutenberg-University in Mainz, Germany and PhD in pharmaceutics from the Johann Wolfgang Goethe-University in Frankfurt. He joined the University of Alberta in 2000. His research interests are in Biopharmaceutics to predict the oral performance of drugs and botanicals and inhalable nanoparticles to treat lung diseases like cancer or tuberculosis. He is founder and director of the Drug Development and Innovation Centre at the University of Alberta. He was president of the Canadian Society for Pharmaceutical Sciences 2014 & 2015. He is member of the United States Pharmacopeia Dietary Supplement Expert Committee. He is Vice Chair of the Specialty Committee of Traditional Chinese Medicine in Pharmaceutics of the World Foundation of Chinese Medicine Science. He is member of the Health Canada Scientific Advisory Committee on Pharmaceutical Sciences and Clinical Pharmacology.Dr. Kamal Dua is an Associate Professor in the Discipline of Pharmacy at the Graduate School of Health, University of Technology Sydney (UTS), Australia. He has research experience of over 13 years in the field of drug delivery systems targeting inflammatory diseases. Dr. Dua is also a Node Leader of Drug Delivery Research in the Centre for Inflammation at Centenary Institute/UTS, where the targets identified from the research projects are pursued to develop novel formulations as the first step towards translation into clinics. Dr. Dua research in two complementary areas; drug delivery and immunology, specifically addressing how these disciplines can advance one another, helping the community to live longer and healthier. This is evidenced by his extensive publication record in reputed journals. Dr. Dua’s research interests focus on harnessing the pharmaceutical potential of modulating critical regulators such as Interleukins and microRNAs and developing new and effective drug delivery formulations for the management of chronic airway diseases. He has published more than 100 research articles in peer-reviewed international journals and authored or co-authored four books. He is an active member of many national and international professional societies.Vinay Parikh is an Associate Professor in the Department of Psychology at Temple University (Philadelphia). He also serves as the Director of Neuroscience Program in Temple’s College of Liberal Arts and provides strategic leadership, direction, and guidance for all educational and professional activities in the program. Dr. Parikh has successfully directed multiple research projects, resulting in notable contributions to the understanding of neural mechanisms underlying cognitive decline in age-related neurodegenerative and psychiatric disorders. His research has also opened new avenues to develop cognition therapies. Dr. Parikh has published more than 90 scientific articles and book chapters in areas of systems and behavioral neuroscience, biological psychiatry, and pharmacology, and serves on several editorial boards of journals. He also regularly serves on scientific advisory and review committees of numerous biomedical research agencies including the National Institute of Health, Alzheimer’s Association, and Michael J Fox Foundation.Dr. Viney Chawla is working as Professor and Principal at University Institute of Pharmaceutical Sciences and Research, Baba Farid University of Health Sciences, Punjab, India, He has 25 Years of experience in the research, formulation and development of solid lipid nanoparticles, microspheres, nanostructured lipid carriers. Dr. Chawla holds a Ph D Degree in Pharmaceutics and has Published 3 Books, 30 Book Chapters and more than 100 Papers in National/International Journals and is serving as a Reviewer for International Journals of repute. He has guided 40 Post Graduate Projects and his research team consists of 9 Masters and 4 Doctoral Research Scholars.

Select Guide Rating

• Part I – Introduction to Drug delivery to the CNS1. General physiology and function of brainAnoop Kumar I2. Drug Delivery to Brain: Formulation Challenges and Potential ApproachesAshish Baldi, Manisha Kumari and Akshay Kumar3. Possible targets in the management of various CNS disordersViney Chawla, Pooja A. Chawla, Ankur Kumar and Bhupender Nehra4. Antioxidants and their possible benefits in neurodegenerationPooja A. Chawla, Viney Chawla, Keshav Taruneshwar Jha and Gouranga Sundar Roy5. Prodrug approaches for delivering CNS active agentsPooja A. Chawla, Viney Chawla, Nikita Sharma and Debashree Debashish Das6. Traditional practices in CNS drug deliveryR K Narang and Pooja A. Chawla7. Emerging need of Novel Drug Delivery Systems in management of CNS disordersViney Chawla, Pooja A. Chawla, Neha Jain, Manisha Pandey, Ms Triveni and Aditi Sinha8. Nose to brain drug delivery through advanced Drug Delivery SystemsMonica Gulati9. PBPK modeling for CNS DeliveryNAGENDRA SINGH CHAUHANPart II – Novel Drug Delivery Systems to specific CNS Disorders10. Superparamagnetic Iron Oxide Nanoparticles and their Potential Role in the Diagnosis and Therapeutics of Various Neurological DisordersBhupinder Singh Bhoop, Anjali Pant, Gurpal Singh, Ravi Pratap Barnwal, Sumant Saini and Atul Jain11. Novel Drug Delivery Systems in treating epilepsyREYAZ HASSAN, Jasreen Uppal and Apporva Chawla12. Novel Drug Delivery Systems in the management of Parkinson’s DiseaseVimal Arora13. Role of Novel Drug Delivery Systems in managing Alzheimer’s DiseaseViney Chawla, Pooja A. Chawla, Ankur Kumar, Bhupender Nehra, Ms Chahat and Abhimannu Shome14. Novel Drug Delivery Systems in the management of Huntington’s DiseaseMonica Gulati15. Novel Drug Delivery Systems in the management of multiple sclerosisDileep Kumar and Gadde Shareena16. Role of Novel Drug Delivery Systems in delivering antidepressant drugs to the brainPooja A. Chawla, Dilpreet Singh, Viney Chawla, Kamal Dua, Amrinder Singh, Ms Amisha and Namandeep Raj17. Delivering cancer chemotherapeutics to the brain through Novel Drug Delivery SystemsPooja A. Chawla18. Novel Drug Delivery Systems in the management of SchizophreniaDileep Kumar and Gadde Shareena19. Prospects of Novel Drug Delivery Systems in treating cerebral palsyMolakpogu Ravindra Babu, Sukriti Vishwas, Monica Gulati, Kamal Dua, Sachin Kumar Singh, Prathap Madeswara Gupta and Palakurthi Yanadaiah20. Novel Treatment in Managing AutismYadu Nandan Dey, Dharmendra Kumar, Manju Singh and Deependra Singh21. Novel Drug Delivery Systems in amyotrophic lateral sclerosisDevidas S. Bhagat, Pooja A. Chawla, Gurvinder S. Bumbrah, Dattatraya Pansare, Bapu R Thorat and Digambar D Gaikwad22. Novel Drug Delivery Systems in cerebral vascular disorders, transient ischaemic attack and stroke interventionsDharmendra Kumar, Deependra Singh and Manju Singh23. Treating meningitis through Novel Drug Delivery SystemsNAGENDRA SINGH CHAUHAN24. Treatment of CNS infections in AIDS positive patients through Novel Drug Delivery SystemsSS Pancholi, Alok Shiomurti Tripathi and Partha Saha25. Novel Drug Delivery Systems in the management of myasthenia gravisDharmendra Kumar26. Etiology and Treatment Challenges for Neurotraumatic and Psychiatric DisordersMohd. Farooq Shaikh and Alina Arulsamy27. Trends in delivery of drugs to brain for treatment of neuropathySukhbir Singh, Neelam Sharma, Ishrat Zahoor and Sandeep Arora28. Delivery of antimigraine drugs to brain through Novel Drug Delivery SystemsManisha Pandey29. Treatment of heavy metal induced neurotoxicity via advanced drug delivery systemsArun Kumar, Mr Abhinav, Mahesh Rachamalla, Mohammad Ali, Sneha Navin, DHRUV KUMAR and Ashok Kumar GhoshPart III – Clinical Trials and Future Prospects30. Exploring the potential of artificial intelligence in drug delivery to brainVimal Arora31. Advanced Drug Delivery Systems in the Management of CNS DisordersShamsher Singh, Pooja A. Chawla, Md Reyaz Alam and Anjalee Bhratee32. Future prospects and Challenges to CNS drug deliverySushama Talegaonkar Sr. and Monalisa Mishra